Skip to main content
OpenTrials
Completed

NCT Number: NCT03399461

Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)

WAS is a rare primary immune deficiency disease caused by genetic mutation and is more common in males than females. The purpose of this study is to understand experiences of WAS subjects and caregivers to identify important concepts of interest that could be measured in future Phase IIIb trials. This is a qualitative cross-sectional study that will include a sample of approximately, 8 subjects with WAS and 13 caregivers of subjects with a diagnosis of WAS in the United States, United Kingdom and France. A 60 to 90 minute open-ended interview will be conducted over the telephone or video conference that will be audio-recorded for subsequent transcription. The aim of these interviews is to obtain subject and caregiver perspectives on the impact of WAS and its associated treatments on quality of life and experiences of living with WAS.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Wiskott-Aldrich Syndrome Blood Coagulation Disorders Blood Coagulation Disorders, Inherited Congenital, Hereditary, and Neonatal Diseases and Abnormalities Cytopenia Genetic Diseases, Inborn Genetic Diseases, X-Linked Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Immune System Diseases Immunologic Deficiency Syndromes Leukocyte Disorders Leukopenia Lymphopenia Primary Immunodeficiency Diseases

Age range

12 year–30 year

Sex eligibility

Male

Study type

Observational

Primary location

GSK Investigational Site

Collegeville, Pennsylvania, 19426, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects:

  • Male adolescents or young adults ranging in age from 12 through 30 years old.
  • Diagnosis of WAS defined by WAS genetic mutation with a clinical score >=1 or self-reported disease severity.
  • Subjects who are "conservatively managed" or have not received treatment for WAS; a maximum of 5 subjects who have received a hematopoietic stem cell transplant within the preceding two years.
  • Able to read, speak, and understand English or French sufficiently to complete all assessments.
  • Willing and able to participate in an audio-recorded, telephone or video conference session, including adherence to the interview instructions and completion of all questionnaires.
  • Parent/guardian/patient signed informed consent.

Caregivers:

  • Caregivers of children >=2 years of age diagnosed with WAS; at least 5 caregivers of subjects under the age of 8.
  • Caregivers of subjects with a diagnosis of WAS defined by WAS genetic mutation with a clinical score >=1 or self-reported disease severity.
  • Caregivers of subjects who are "conservatively managed" or have not received treatment for WAS; At least 2 caregivers of subjects who have received a hematopoietic stem cell transplant within the preceding two years.
  • Caregivers are defined as primary caregiver.
  • Able to read, speak, and understand English or French sufficiently to complete all assessments.
  • Willing and able to participate in an audio-recorded, telephone or video conferencing interview session, including adherence to the interview instructions and completion of all questionnaires.
  • Caregivers of Wiskott-Aldrich patients can be of any age or gender and do not have to follow the patient inclusion criteria, as long as their child/patient meets the inclusion criteria, as outlined.

Exclusion criteria

Subjects

  • Subjects who have previously received gene therapy treatment Caregivers
  • Caregivers of subjects who have previously received gene therapy treatment
  • Professional caregivers (that is, at home nurse or equivalent).

Treatment and study plan

Patient Interview guide

Other

The interviewer will conduct the interview for subjects with WAS using a semi-structured patient interview guide.

Caregiver interview guide

Other

The interviewer will conduct the interview for caregivers of subjects with WAS using a semi-structured caregiver interview guide.

Sociodemographic questionnaire

Other

At the end of interview, subjects will be required to complete subject or caregiver versions of country-specific sociodemographic questionnaire.

Pediatric quality of life (PedsQL) questionnaire

Other

The PedsQL is a validated generic measure of health-related quality of life (HRQOL) in children, adolescents, and young adults with acute and chronic health conditions. At the end of interview, subjects will be required to complete subject or caregiver versions of PedsQL questionnaire.

Clinical Questionnaire

Other

At the end of interview, subjects will be required to complete subject or caregiver versions of clinical questionnaire.

Primary outcomes

  1. Number of subject reported perspectives on WAS

    Time frame: Up to 90 minutes

    Open-ended interviews will be conducted in adolescent and adult subjects to understand their perspective on WAS.

  2. Number of caregiver reported perspectives on WAS

    Time frame: Up to 90 minutes

    Open-ended interviews will be conducted in caregivers of subjects with WAS to understand their perspective on WAS.

  3. Number of subject reported preventative measures taken to avoid infection and bleeding

    Time frame: Up to 90 minutes

    The preventative measures taken to avoid infection and bleeding as reported by subjects during open-ended interviews will be summarized.

  4. Number of caregiver reported preventative measures taken to avoid infection and bleeding

    Time frame: Up to 90 minutes

    The preventative measures taken to avoid infection and bleeding as reported by caregivers during open-ended interviews will be summarized.

  5. Number of subject reported awareness on the risk of disease

    Time frame: Up to 90 minutes

    Open-ended interviews will be conducted in adolescent and adult subjects to understand their awareness on the risk of disease (that is, risk of future complications and potential rapid decline).

  6. Number of caregiver reported awareness on the risk of disease

    Time frame: Up to 90 minutes

    Open-ended interviews will be conducted in caregivers of WAS subjects to understand their awareness on the risk of disease (that is, risk of future complications and potential rapid decline).

  7. Number of treatment sequences received by subjects

    Time frame: Up to 90 minutes

    Open-ended interviews will be conducted to understand the treatments received by subjects in terms of sequencing.

  8. Number of subject reported reasons for discontinuation or change in treatment option

    Time frame: Up to 90 minutes

    Open-ended interviews will be conducted in adolescent and adult subjects to understand reasons for discontinuation or change in treatment option for WAS.

  9. Number of caregiver reported reasons for discontinuation or change in treatment option

    Time frame: Up to 90 minutes

    Open-ended interviews will be conducted in caregivers of WAS subjects to understand reasons for discontinuation or change in treatment option for WAS.

  10. Analysis of tolerability of treatment by subjects

    Time frame: Up to 90 minutes

    Open-ended interviews will be conducted in subjects and caregivers to understand the tolerability of WAS treatment by subjects.

  11. Number of subject reported treatment burden

    Time frame: Up to 90 minutes

    Open-ended interviews will be conducted in adolescent and adult subjects to analyze treatment burden for subjects.

  12. Number of caregiver reported treatment burden

    Time frame: Up to 90 minutes

    Open-ended interviews will be conducted in caregivers of WAS subjects to analyze treatment burden for caregivers.

  13. Number of subject reported perspectives on the risk associated with treatment

    Time frame: Up to 90 minutes

    Open-ended interviews will be conducted in adolescent and adult subjects to understand their perspective on the risks associated with each treatment.

  14. Number of caregiver reported perspectives on the risk associated with treatment

    Time frame: Up to 90 minutes

    Open-ended interviews will be conducted in caregivers of WAS subjects to understand their perspective on the risks associated with each treatment.

  15. Number of key concepts of interest

    Time frame: Up to 90 minutes

    Open-ended interviews will be conducted to identify the important concepts of interest that may be used in future clinical trials.

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Understanding of the Patient and Caregiver Experience of Wiskott-Aldrich Syndrome (WAS)

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Jan 16, 2018
Registry last updated
Mar 14, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.